Department / Division
Medicine / Medicine-Endocrinology and Metabolism
Durham, NC 27710
Osteoporosis and metabolic bone disease including male osteoporosis, transplantation osteoporosis, male hypogonadism; secondary osteoporosis including glucocorticoid induced, familial and acquired hypophosphatemic disorders
Osteoporosis, with current studies that focus on advances in diagnosis and natural history of male and postmenopausal osteoporosis. The study on male osteoporosis include a collaborative study with outside investigators is examining the utility of lateral spine bone densitometry in identifying men with osteoporosis and low trauma fractures.
Hypophosphatemic disorders, including X-link hypophosphatemic rickets and tumor-induced osteomalacia. My ongoing research study, in collaboration with Dr. L Darryl Quarles at the University of Kansas, seeks to further confirm and extend our understanding of the role of FGF-23 in human disorders of phosphate homeostasis, including patients with chronic kidney disease. Pending studies include primary and sub-investigator directed Phase 1 / 2 first in human studies examining the effects of a monoclonal antibody and enzyme replacement therapy for X-linked hypophosphatemic rickets and hypophosphatasia, respectively.
This faculty member has no reported relationships with industry.
Case, LE; Hanna, R; Frush, DP; Krishnamurthy, V; DeArmey, S; Mackey, J; Boney, A; Morgan, C; Corzo, D; Bouchard, S; Weber, TJ; Chen, YT; Kishnani, PS. Fractures in children with Pompe disease: a potential long-term complication. Pediatric Radiology: roentgenology, nuclear medicine, ultrasonics, CT, MRI. 2007;37:437-445. (2007) Abstract
Weber, TJ; Liu, S; Indridason, OS; Quarles, LD. Serum FGF23 levels in normal and disordered phosphorus homeostasis. Journal of Bone and Mineral Research. 2003;18:1227-1234. (2003) Abstract
Weber, TJ; Drezner, MK. Effect of alendronate on bone mineral density in male idiopathic osteoporosis. Metabolism: clinical and experimental. 2001;50:912-915. (2001) Abstract